PDR 001

Drug Profile

PDR 001

Alternative Names: PDR001

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Dana-Farber Cancer Institute; Novartis; Novartis Oncology
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase II Nasopharyngeal cancer; Neuroendocrine tumours
  • Phase I/II Solid tumours
  • Phase I Acute myeloid leukaemia; Breast cancer; Cancer; Colorectal cancer; Hepatocellular carcinoma; Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 18 Oct 2017 Phase-I clinical trials in Breast cancer and Ovarian cancer (Combination therapy, Metastatic disease) in USA (IV) (NCT03294694)
  • 04 Oct 2017 Dana-Farber Cancer Institute and Novartis plan a phase I trial for Breast cancer and Ovarian cancer (Combination therapy, Metastatic disease) in USA (NCT03294694)
  • 25 Sep 2017 Phase-I clinical trials in Colorectal cancer (Metastatic disease, First-line therapy, Combination therapy) in United Kingdom, Australia (IV) (NCT03176264)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top